High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia: A single center study

American Journal of Clinical Pathology

Volumn 113, Issue 3, 2000, Pages 406-410

  Mitterbauer, M ^a   Laczika, K ^a   Novak, M ^a   Mitterbauer, G ^c   Hilgarth, B ^a   Pirc Danoewinata, H ^b   Schwarzinger, I ^c   Haas, O A ^b,c   Fonatsch, C ^c   Lechner, K ^a   Jaeger, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute myeloid leukemia; CBF beta MYH11; inv(16); Reverse transcriptase polymerase chain reaction; RT PCR

Indexed keywords

BINDING PROTEIN; CORE BINDING FACTOR BETA; MYOSIN HEAVY CHAIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME 16; CHROMOSOME ANALYSIS; CHROMOSOME INVERSION; CLINICAL ARTICLE; FEMALE; HUMAN; KARYOTYPING; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 18144445206     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/d94u-351n-ht3d-f1f3     Document Type: Article

References (37)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
2. Rowley JD. Recurring chromosomal abnormalities in leukemia and lymphoma. Semin Hematol. 1990;27:122-136.
3. Bitter MA, LeBeau MM, Rowley JO, et al. Association between morphology, karyotype and clinical features in myeloid leukemias. Hum Pathol. 1987;18:211-225.
4. Berger R, Flandrin G, Bernheim A, et al. Cytogenetic studies on 519 consecutive de novo acute nonlymphoblastic leukemias. Cancer Genet Cytogenet. 1987;29:9-21.
5. Sawyers CL Molecular genetics of acute leukemia. Lancet. 1997;349:196-200.
6. Schiffer CA, Lee EJ, Tomiyasu T, et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989;73:263-270.
7. Mitelman F, Heim S. Quantitative acute leukemia cytogenetics. Genes Chromosomes Cancer. 1992;5:57-66.
8. Enright H, Weisdorf D, Peterson L, et al. Inversion of chromosome 16 and dysplastic eosinophils in accelerated phase of chronic myeloid leukemia. Leukemia. 1992;6:381-384.
9. Asou N, Sanada I, Tanaka K, et al. Inversion of chromosome 16 and bone marrow eosinophilia in a myelomonocytic transformation of chronic myeloid leukemia. Cancer Genet Cytogenet. 1992;61:197-200.
10. Estey E, Trujillo JM, Cork A, et al. AML-associated cytogenetic abnormalities (inv(16), del(16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol. 1992;6:43-48.
11. Bloomfield CD, Lawrence D, Arthur DC, et al. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood. 1994;84(suppl1):111a. Abstract.
12. Ghaddar HM, Plunkett W, Kantarjian HM et al. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia. 1994;8:1269-1274.
13. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
14. Tashiro S, Kyo T, Tanaka K, et al. The prognostic value of cytogenetic analysis in patients with acute nonlymphocytic leukemia treated with the same intensive chemotherapy. Cancer. 1992;70:2809-2815.
15. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and myosin heavy chain in acute myeloid leukemia. Science. 1993;261:1041-1044.
16. Liu PP, Hajra A, Wijmenga C, et al. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood. 1995;85:2289-2302.
17. Claxton DF, Liu P, Hsu HP, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myeloid leukemia. Blood. 1994;83:1750-1756.
18. van der Reijden BA, Lombardo M, Dauwerse HC, et al. RT-PCR diagnosis of patients with acute nonlymphatic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBF beta-MYH11 transcripts. Blood. 1995;86:277-282.
19. Poirel H, Radford-Weiss I, Rack K, et al. Detection of chromosome 16 CBF beta-MYH11 fusion transcript in myelomonocytic leukemias. Blood. 1995;85:1313-1322.
20. Shurtleff SA, Meyers S, Hiebert SW, et al. Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood. 1995;85:3695-3703.
21. Hebert J, Cayuela JM, Daniel MT, et al. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Blood. 1994;84:2291-2296.
22. Evans PAS, Short MA, Jack AS, et al. Detection and quantification of the CBF beta/MYH11 transcripts associated with the inversion (16) in presentation and follow-up samples from patients with AML. Leukemia. 1997;11:364-369.
23. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodological advances and clinical significance. Blood. 1995;85:1416-1434.
24. Tobal K, Johnson PRE, Saunders MJ, et al. Detection of CBF beta/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol 1995;91:104-108.
25. Laczika K, Novak M, Hilgarth B, et al. Competitive CBF beta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion (16): a pilot study. J Clin Oncol. 1998;16:1519-1525.
26. Langabeer SE, Walker H, Gale RE, et al. Frequency of CBF beta/MYH11 fusion transcripts in patients entered into U.K. MRC AML trials. Br J Haematol. 1997;96:736-739.
27. Ritter M, Thiede C, Schakel U, et al. Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation. Br J Haematol. 1997;98:969-972.
28. Krauter J, Peter W, Pascheberg U, et al. Detection of karyotypic aberrations in acute myeloblastic leukemia: a prospective comparison between PCR/FISH and standatd cytogenetics in 140 patients with de novo AML. Br J Haematol. 1998;103:72-78.
29. Mitelman F, ed. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S Karger; 1991.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroforrn extraction. Anal Biochem. 1987;162:156-159.
31. Kwok S, Higuchi R. Avoiding false positives with the PCR. Nature. 1989;339:327-328.
32. Ng S-Y, Gunning P, Eddy R, et al. Evolution of the functional human beta-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes. Mol Cell Biol. 1985;5:2720-2732.
33. Novak M, Laczika K, Mitterbauer M, et al. Novel CBF beta/MYH11 fusion transcripts and alternative splicing in acute myeloid leukemia with inversion of chromosome 16 [letter]. Blood. 1994;86:2449-2450.
34. Langabeer SE, Walker H, Rogers JR, et al. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. Br J Haematol. 1997;99:925-928.
35. Mitterbauer M, Kusec R, Schwarzinger I, et al. Comparison of karyotype analysis and RT-PCR for AML1/ETO in 204 unselected patients with AML. Ann Hematol. 1998;76:139-143.
36. Ganesan TS, Rassool F, Guo AP, et al. Rearrangement of the bcr gene in Philadelphia chromosome-negative chronic myeloid leukemia. Blood. 1986;68:957-960.
37. Viswanatha DS, Ming Chen I, Liu PP, et al. Characterization and use of an antibody detecting the CBF beta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias. Blood. 1998;91:1882-1890.